TargetMol

8-Cyclopentyl-1,3-dimethylxanthine

Product Code:
 
TAR-T27076
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27076-5mg5mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27076-1mL1 mL * 10 mM (in DMSO)£113.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27076-10mg10mg£118.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27076-25mg25mg£156.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27076-50mg50mg£193.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27076-100mg100mg£244.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27076-200mg200mg£332.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27076-500mg500mg£462.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
8-Cyclopentyl-1,3-dimethylxanthine?is a potent antagonist of adenosine A1 receptor.
CAS:
35873-49-5
Formula:
C12H16N4O2
Molecular Weight:
248.286
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.95
SMILES:
Cn1c2nc([nH]c2c(=O)n(C)c1=O)C1CCCC1
Target:
Adenosine Receptor

References

1. Liu Y , Mei H , Zhu G , et al. Congenital pseudarthrosis of the tibia in children: should we defer surgery until 3 years old?[J]. Journal of Pediatric Orthopedics Part B, 2017:17. 2. Vigouroux F, Mezzadri G, Parot R, Gazarian A, Pannier S, Chotel F. Vascularised Fibula or Induced Membrane to Treat Congenital Pseudarthrosis of the Tibia: A Multicentre Study of 18 Patients with a Mean 9.5-Year Follow-Up. Orthop Traumatol Surg Res. 2017 May 27. pii: S1877-0568(17)30147-0. doi: 10.1016/j.otsr.2017.05.00[Epub ahead of print] PubMed PMID: 28559144. 3. Sanche S, Sheehan N, Mespl?de T, Wainberg MA, Li J, Nekka F. A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration. CPT Pharmacometrics Syst Pharmacol. 2017 May 27. doi: 10.1002/psp4.12200. [Epub ahead of print] PubMed PMID: 28556627. 4. Hallow KM, Gebremichael Y. A Quantitative Systems Physiology Model of Renal Function and Blood Pressure Regulation: Application in Salt-Sensitive Hypertension. CPT Pharmacometrics Syst Pharmacol. 2017 May 27. doi: 10.1002/psp4.12177. [Epub ahead of print] PubMed PMID: 28556624.